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Abstract: Background: The central vein sign (CVS) is a radiological feature proposed as a multiple
sclerosis (MS) imaging biomarker able to accurately differentiate MS from other white matter diseases
of the central nervous system. In this work, we evaluated the pooled proportion of the CVS in brain
MS lesions and to estimate the diagnostic performance of CVS to perform a diagnosis of MS and
propose an optimal cut-off value. Methods: A systematic search was performed on publicly available
databases (PUBMED/MEDLINE and Web of Science) up to 24 August 2020. Analysis of the proportion
of white matter MS lesions with a central vein was performed using bivariate random-effect models.
A meta-regression analysis was performed and the impact of using particular sequences (such as 3D
echo-planar imaging) and post-processing techniques (such as FLAIR*) was investigated. Pooled
sensibility and specificity were estimated using bivariate models and meta-regression was performed
to address heterogeneity. Inclusion and publication bias were assessed using asymmetry tests and
a funnel plot. A hierarchical summary receiver operating curve (HSROC) was used to estimate
the summary accuracy in diagnostic performance. The Youden index was employed to estimate
the optimal cut-off value using individual patient data. Results: The pooled proportion of lesions
showing a CVS in the MS population was 73%. The use of the CVS showed a remarkable diagnostic
performance in MS cases, providing a pooled specificity of 92% and a sensitivity of 95%. The optimal
cut-off value obtained from the individual patient data pooled together was 40% with excellent
accuracy calculated by the area under the ROC (0.946). The 3D-EPI sequences showed both a higher
pooled proportion compared to other sequences and explained heterogeneity in the meta-regression
analysis of diagnostic performances. The 1.5 Tesla (T) scanners showed a lower (58%) proportion of
MS lesions with a CVS compared to both 3T (74%) and 7T (82%). Conclusions: The meta-analysis we
have performed shows that the use of the CVS in differentiating MS from other mimicking diseases
is encouraged; moreover, the use of dedicated sequences such as 3D-EPI and the high MRI field
is beneficial.
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1. Introduction
Multiple sclerosis (MS) is one of the most common autoimmune disorders of the central
nervous system (CNS), characterized by diffuse inflammatory/demyelinating and neurodegenerative
alterations [1]. Magnetic resonance imaging (MRI) is one of the most powerful technological
aids supporting MS diagnosis which can be used to demonstrate the distinctive dissemination
in space and time of the disease. Over time, the diagnostic criteria, also implementing MRI in the
diagnostic process, have increased their sensitivity, allowing an even earlier MS diagnosis, after a
first/isolated event suggestive of acute CNS demyelination [2]. However, their specificity remains
limited, especially in the presence of atypical history, and this could result in misdiagnosis and
initiation/delay of inappropriate/approved disease-modifying treatment [3]. Brain MRI findings in
conventional T2-weighted sequences in patients with different morbidities, such as vasculopathies,
migraine and non-MS CNS demyelinating or autoimmune disorders, may be mistakenly suggestive
of MS lesions [4]. Therefore, more MS-specific MRI criteria to rule out MS-mimicking disorders
are needed.
The central vein sign (CVS), a recent radiological feature developed initially in ultra-high field
MRI studies [5,6], relying on the pathological specificity of perivenular distribution of MS lesions [7],
has been proposed as an MS imaging biomarker able to accurately differentiate MS from other white
matter (WM) diseases of the CNS.
Although a definition of the CVS has been provided by an expert consensus, briefly as a distinct
vein centrally located in a clearly visible MS lesion > 3 mm in diameter irrespective of its location in
supratentorial brain white matter [8], and criteria based on both proportion lesion threshold [9,10] or lesion
number threshold [11,12] have been proposed to discriminate MS from its MRI mimics, the lack of both a
standardized imaging acquisition protocol and an accurate (and routinely suitable) CVS evaluation
approach in suspected MS cases currently still prevent the applicability of this potential biomarker.
Imaging of a central vein in MS lesions can be achieved by exploiting the ability of
susceptibility (T2*-“T2-star”)-based MRI sequences to highlight in vivo paramagnetic properties
of deoxyhemoglobin in venous blood flow [13]. By combining both magnitude and phase images
acquired using T2*-weighted (T2*w) gradient echo (GRE) pulse sequences, it is possible to exploit
susceptibility-weighted imaging (SWI) that can reveal the presence of blood vessels in MS lesions [14,15].
Even though the core protocol always includes a GRE sequence, a great variety of MRI parameters
can be utilized to obtain SWI [14]. For instance, some studies introduced the use of echo-planar
imaging (EPI) that allows for the retrieval of high-resolution images while reducing the scan time [16].
Further heterogeneity in the studies is introduced by the post-processing implementation. The first
processing step required to compute SWI is the removal of artifacts from phase images. Several
different phase processing approaches have been tested where high-pass filters are applied directly to
phase images or following phase unwrapping [17]. Besides obtaining SWI from the combination of
both magnitude and phase from the same GRE acquisition, another strategy consists of multiplying
a T2*-weighted sequence with the fluid-attenuated inversion recovery (FLAIR) sequence to obtain a
FLAIR* image [18]. This approach combines the sensibility of FLAIR in detecting WM lesions and the
ability of susceptibility-based imaging to highlight the presence of the vein (Figure 1).
In this meta-analytic study, we aim to systematically review the proportion of MS white matter
lesions which show the CVS (MSL Vein+) and estimate the performance diagnostic value, in terms of
specificity, sensitivity and accuracy, in discriminating MS from its common radiological differential
diagnosis, aiming to endorse its usefulness in clinical practice. Moreover, we further investigate
the impact of using different field strengths, specific sequences (i.e., 3D echo-planar imaging) and
post-processing techniques (i.e., SWI, FLAIR*).
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Figure 1. Example of multiple sclerosis (MS) patient MRI images obtained with sequences to detect 
the central vein sign (CVS). T2*-weighted 3D echo-planar imaging (EPI), 3D fluid-attenuated 
inversion recovery (FLAIR) and FLAIR*, a post-processing technique that combines the EPI sequence 
[or more generally a T2*w sequence (used to detect CVS)] and FLAIR. The orange arrowheads 
indicate MS lesions with the characteristic CVS. A zoomed-in version of the same image is reported 
to highlight the CVS feature for each modality. 
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2. Materials and Methods 
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statement [19,20]. The methodological framework used in this review is consistent with a previously 
published review and meta-analysis on the topic [21,22]. 
2.1. Literature Search: Databases and Search Phrase 
Systematic research over two major databases was conducted following a recent systematic 
review and meta-analysis guideline [23]. PUBMED/MEDLINE and Web of Science were selected to 
look for articles using the CSV criteria to strengthen the MS diagnosis capability. The search string 
used in both databases was: (((“multiple sclerosis”) AND ((“central vein”) OR ((“vein”) AND 
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CVS feature for each modality.
2. Materials and Methods
The systematic review and meta-analysis were performed following the Preferred Reporting
Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy (PRISMA-DTA)
statement [19,20]. The methodological framework used in this review is consistent with a previously
published review and meta-analysis on the topic [21,22].
2.1. Literature Search: Databases and Search Phrase
Systematic research over two major databases was conducted following a recent systematic review
and meta-analysis guideline [23]. PUBMED/MEDLINE and Web of Science were selected to look for
articles using the CSV criteria to strengthen the MS diagnosis capability. The search string used in
both databases was: (((“multiple sclerosis”) AND ((“central vein”) OR ((“vein”) AND (“lesion”)) OR
(“perivenular”))). The literature research included only papers written in English and published up to
24 August 2020. The management of the literature research was conducted with Zotero (v 5.0.90).
2.2. Eligibility Criteria
Among studies retrieved from searched databases, we selected only published peer-reviewed
studies that met all the following criteria: studies including patients with MS; studies evaluating the
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CSV. Furthermore, we included studies that provided either the prevalence of the CSV in white matter
lesions or true positives (TPs), false negatives (FNs), true negatives (TNs) and false positives (FPs) in
diagnosing MS using the CVS.
We excluded from the review and from the meta-analysis any paper that met any of the following
criteria: conference proceedings; animal-based studies; reviews; case reports and papers with fewer
than five cases; editorial notes, surveys and guidelines.
2.3. Paper Summary and Data Extraction
The prevalence of the CVS in MS lesions and its diagnostic performance in differentiating MS from
other diseases were separately summarized for each article included in the review. The CVS has been
recently defined by the guidelines of the North American Imaging in Multiple Sclerosis Cooperative
(NAIMS Cooperative) [8]. Accordingly, in this review, a central vein was defined as exhibiting the
following properties in T2*-weighted images:
• Appears as a thin hypointense line or small hypointense dot;
• Has a small apparent diameter;
• Runs partially or entirely through the lesion;
• Is positioned centrally in the lesion, regardless of the lesion’s shape.
Some studies (i.e., those published before the NAIMS Cooperative consensus paper) were included
in this review, although the exclusion criteria for scoring the CVS according to the NAIMS Cooperative
consensus were fulfilled (i.e., confluent lesion evaluation).
Diagnostic performances in terms of TP, FN, TN and FP for each study were recorded when
available or were derived if not explicitly stated in the paper. Moreover, for each study, we also
reported: study design (prospective/retrospective), the number of patients in the MS cohort and in the
control group; sub-division between MS phenotypes; differential diagnosis; age (mean and interval)
of both the MS and the control group; magnetic field strength; sequence used in the evaluation of
the CVS; use of contrast agent; the number of readers and their background and blindness to the
reference standard; institution and type of study (mono-/multi-centric); cut-off for the prevalence of the
CVS in MS lesions and rule used (if multiple thresholds/criteria/rules were used, only the overall best
diagnostic performance, in terms of the maximum sum of specificity and sensitivity, was retained).
2.4. Statistical Analysis
Estimations of pooled incidence of the central vein sign in T2*-based MRI acquisition in patients
with MS were carried out using a random-effects meta-analysis weighted with the inverse variance
supporting DerSimonian–Laird’s method [24]. Heterogeneity between studies was quantified by the
Higgins inconsistency test through the I2 index which is not directly influenced by the number of
the studies included in the analysis. The I2 index lies between 0% and 100%. A value of 0% implies
no observed heterogeneity, while larger values indicate increasing heterogeneity (25, 50 and 75%
indicate low, medium and high heterogeneity, respectively). Publication bias was detected by funnel
plots and the asymmetry was assessed by Egger’s test. To explain the effects of study heterogeneity,
a meta-regression analysis was performed using the study design (prospective study vs. others),
post-processing image technique (FLAIR* vs. others), MRI sequence ( 3D-EPI vs. others), reader
(radiologist vs. other), patient age (age median ≤ average age weighted on patient number vs. age
median > age weighted on patient number), use of the contrast agent before the acquisition of the
T2*-weighted sequence (used vs. not used) and blindness to the reference standard as covariates.
Sub-group analysis was performed to test the single effect of the scanner magnetic strength (1.5 Tesla
(T) vs. 3T vs. 7T), type of post-processing employed (FLAIR* vs. others) and MRI sequence employed
(3D-EPI vs. others). The proportional meta-analysis conducted on both the complete set of studies
included in this work and separately for each sub-group was preceded by an influence analysis to
identify outliers in each set or subset [25].
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The bivariate random-effects model was made in order to calculate the pooled sensitivity and
specificity for the diagnostic accuracy of the central vein sign for differentiating MS from other common
differential diagnoses. The estimated sensitivity and specificity and the credible intervals for each
study were reported in a forest plot. The hierarchical summary receiver operating characteristic
(HSROC) curve with 95% confidence and prediction regions was plotted. The extent of heterogeneity
was assessed using the Cochran Q-test, the Higgins I2 test and the Spearman correlation coefficient
(rho) between sensitivity and false positive rate. Possible publication bias was evaluated by Deeks’
funnel plot and assessed with a regression test on the diagnostic odds ratio. A p-value < 0.05 was
considered as indicative of statistical significance.
A bivariate meta-regression model was applied to evaluate the effects of study heterogeneity
using the following seven covariates: study design (prospective study vs. others), post-processing
technique (FLAIR* vs. others), MRI sequence (3D-EPI vs. others), reader (radiologist vs. other),
patient age (age median ≤ average age weighted on patient number vs. age median > age weighted
on patient number), use of the contrast agent before the acquisition of the T2*-weighted sequence
(used vs. not used) and blindness to the reference standard. Finally, subgroup analysis was performed
using the proportion of lesions with the central vein sign as a cut-off value on those studies providing
individual patient data. The individual data were extracted from the text of the articles or estimated
from the plots indicating the proportion of lesions with the central vein sign using Web Plot Digitizer
v. 4.3 (https://automeris.io/WebPlotDigitizer/) when data were not reported. The optimal threshold in
ROC analysis was defined using the Youden index method [26]. Specifically, the Youden index was
applied to estimate the optimal cut-off value for the proportion of lesions with the central vein sign
and the corresponding sensitivity and specificity (95% CI). The Youden index is defined as sensitivity +
specificity -1, with it having a minimum value of −1 and a maximum value of + 1, with a value of + 1
indicating the optimal value for an algorithm. Statistical analysis was performed using the “metafor”,
“mada” and “meta4diag” packages in R v. 3.5 and the “metandi” and “midas” modules in STATA 16.1.
3. Results
3.1. Literature Review
A total of 278 studies were screened according to the Preferred Reporting Items for a Systematic
Review and Meta-analysis of Diagnostic Test Accuracy (PRISMA-DTA) (Figure 2). For subsequent
qualitative and quantitative analysis, a total of 35 studies were considered eligible. A total of
1047 patients, including clinically isolated syndrome (CIS; n = 256) or definite multiple sclerosis
(MS; n = 791), were included in the analysis.
3.2. Features of the Eligible Studies
Eleven studies used a prospective design [9,27–36], while ten reported a retrospective
one [11,12,37–44]. The remaining fourteen did not mention the design type or the studied cohort
was partially collected prospectively and retrospectively [10,38,45–56]. The mean number ± standard
deviation of MS patients included in each study was 45.3 ± 70.78 (range: 5–323).
Five studies used a 1.5T scanner [27,38,39,42,43], twenty-one a 3T scanner [11,12,28–33,35–37,40,
46–48,51–55,57] and six a 7T scanner [10,34,41,45,50,58]. The remaining studies used images acquired
at multiple field strengths: one study used either 1.5T or 3T but did not provide the proportion of CVS
lesions for each scanner and thus was excluded from the sub-group analysis based on the scanner field
strength [9]; two studies used both 3T and 7T scanners, however, in our meta-analysis, only the results
from the highest field strength were reported as they provided the best performance [49,56].
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Accuracy (PRISMA-DTA) flow diagram to select studies to be included in the subsequent meta-analysis.
Even though all the eligible studies included a susceptibility-based sequence (either susceptibility-
weighted images, SWI; T2*-weighted gradient echo, T2*w; or T2*-weighted 3D echo-planar imaging,
3D-EPI), several protocols and processing techniques have been reported. Of the three studies detecting
the CVS i T2*w images [45,50,58], one selected contrast-enhanci g lesions using post-contrast
images [45]. Of the fifteen studies using SWI [27,30,32,35,37–43,47,48,52,54] to id ntify the central vein
sign, one add d to the MRI protocol post-c ntrast s quences to select contrast-enhancing lesions [39],
eight added a FLAIR sequenc [30,35,40,42,47,48,52, 4], one added a conventional T2-weighted
acquis tions [32] and four added both FLAIR and conventional T2-w ighted a quisitions [27,37, 8 43],
to delineate white matter lesions. Six studies employed a T2*w EPI sequence [10,11,33,34,46,57]
nd eight s udies acquire both EPI and FLAIR sequences [9,12,28,29,36,49,53] that were combined
to btain FLAIR* image in s ven of th se studie [9,12,28,29,31,36,53]. Of the remai ing studi s,
e r trieved FLAIR* images from the post-processing of 3T FLAIR and t e phase of a 7T SWI
sequence [56], on used multiple susceptibility-weighted qualitativ and qu ntitative images (SWI and
R2*, respe tively) [55] and one was a multicentric study including a heterogeneous set of MRI
sequenc s [51]. In ten of the elig ble studies, the susceptibility-ba ed sequence was acquir d during o
after the injection of he contra t agent [9,12,28,30,31,39,40,47,53].
3.3. MS Lesions with Central Vein Pooled Proportion
Among the studies included, twenty-nine provided information on the proportion of MS lesions
with the central vein sign [10–12,27–30,32–40,42,43,47–52,54–56,58,59]. The proportion of lesions
with a central vein sign ranged from 0.4 up to 0.92. The pooled proportion of central vein signs in
MS lesions considering all the studies included was 0.73 (95% CI, 0.67–0.79 (Figure 3). Influence
analysis to detect outliers did not find any study that largely impacted on the pooled proportion.
The Higgins inconsistency test showed high heterogeneity (I2 = 98%). The meta-regression carried out
to describe this heterogeneity did not find any statistical significance among the modeled covariates.
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The publication bias assessment performed with the funnel plot showed no asymmetry (Supplementary
Figure S1) and Egger’s test showed no statistically significant asymmetry (p = 0.074).
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Figure 3. Forest plot showing the proportion of MS lesions with central vein sign (MSL Vein+) and
the weight in the Random effect model for each study considered. Proportions are reported with
estimated 95% confidence intervals (C.I.). In bold are reported the total number of MS lesions, the
pooled proportions and the pooled C.I. and the total weights.
Regarding the effect of the scanner magnetic strength (1.5T vs. 3T vs. 7T), we did not find any
study largely driving any subgroup. Moreover, the pooled proportion of central veins obtained with
1.5T MRI scanners was 0.58 (95% CI, 0.47–0.68). It was statistically different compared to the proportion
obtained with both 3T (0.74 - 95% CI, 0.66–0.81, p = 0.011) and 7T (0.82 - 95% CI, 0.67–0.91, p = 0.011)
scanners (Supplem ntary Figure S2). There was no statistically significa t difference in the pooled
proportion between 3T and 7T (p = 0.32).
The type of the post-processing employed (FLAIR* vs. others) did not show any influential
study nor any statistically significant difference in the pooled proportion, that was 0.77 (95%
CI, 0.61–0.87) when employing the FLAIR* and 0.74 (95% CI, 0.66–0.80) when it was not used
(Supplementary Figure S3).
The MRI sequence used in the acquisition (3D-EPI vs. others) showed a study influencing the
pooled proportion in the 3D-EPI sub-group [48], that was excluded from further sub-group analysis.
After removing this outlying study, the proportion of lesions showing a central vein when using 3D-EPI
was 0.82 (95% CI, 0.76–0.87) and it was statistically significantly higher (p = 0.018) compared to the use
of other sequences (0.71 - 95% CI, 0.62–0.78, Supplementary Figure S4).
3.4. MS Diagnostic Accuracy Measured by Pooled Sensitivity and Specificity
Eighteen studies [9–12,27,28,32–35,41,44,47,48,51–53] provided the data to perform a pooled
diagnostic accuracy meta-analysis. The pooled sensitivity and pooled specificity were 95% (95% CI,
90–99%) and 92% (95% CI, 87–97%), respectively (Figure 4, Figure 5). The area under the HSROC
curve was 0.98 (95% CI, 0.96–0.99%) (Figure 6). Both the Q-test (Q = 18.915, p = 0.333) and the Higgins
I2 (10.12) suggested low heterogeneity across the studies. Both the forest plots and the Spearman
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correlation (rho = −0.18, 95% CI, −0.595–0.316) coefficient revealed no evidence of a threshold effect.
Publication bias was detected by Deeks’ funnel plot (p < 0.001, Supplementary Figure S5).
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In the meta-regression, among the covariates, only the MRI sequence (p = 0.04) significantly
affected the heterogeneity. Other covariates, including study design (p = 0.24), reader blindness to the
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reference standard (p = 0.48), age (p = 0.06), reader (p = 0.48) and post-processing technique (p = 0.20),
did not show statistical differences.
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3.5. Diagnostic Performance using Distinct Patient ata
Fifteen studies reported the single patient percentage of lesions with a central vein [9–11,27,28,32,
34,36,41,46,48,50,52,57,58]. The number of considered MS patients was 284, while 178 were patients
with other diseases or healthy controls (58% of MS patients). The cut-off values among the considered
distinct patients ranged from 0 to 100 with a median value of 54%. The area under the ROC curve of the
proportion of lesions with the central vein sign for the diagnosis of MS was 0.946 (95% CI, 0.924–0.967)
(Figure 7). The optimal cut-off value identified by the Youden approach was 40%, with a sensitivity of
90% (95% CI, 81–95%) and a specificity of 89% (95% CI, 82%–96%).
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4. Discussion
Evaluating the role of more specific magnetic resonance imaging (MRI) features of multiple
sclerosis (MS) lesions, such as the central vein sign (CVS), is considered a high-priority area for research
according to The International Panel on Diagnosis of MS, which produced the 2017 revised diagnostic
criteria [60].
The systematic review and meta-analysis we performed aimed to assess the prevalence of the CVS
in white matter (WM) MS brain lesions with respect to other WM diseases, as well as to investigate the
use of the CVS in the differential diagnosis of MS by suggesting an optimal cut-off to differentiate MS
from other conditions with MRI T2 hyperintensities and analyze the diagnostic performance measured
with pooled sensitivity and specificity.
In this regard, the pooled proportion analysis revealed a high proportion (73%) of lesions showing
a CVS in MS. Moreover, the use of the CVS reported a notable diagnostic performance, providing a
pooled specificity of 92% and sensitivity of 95%. The pooled diagnostic performances in differentiating
MS from other diseases estimated with the area under the HSROC of 0.98 (95% CI, 0.96–0.99%) revealed
an excellent performance in this task. The optimal cut-off value obtained from the single patient data
pooled together was 40% with an excellent value of the accuracy calculated by the area under the ROC
(0.946). The heterogeneity in the dataset is high and this can be explained by the various features and
settings of the eligible studies in terms of sequence, scanner field strength, post-processing technique
and control group (both MS mimics and healthy control groups were considered). Nevertheless,
the analysis conducted supports the potential role of the CVS in the diagnostic work-up of MS.
Among several neuropathological features that characterize MS lesions, despite their different and
asynchronous evolutive aspects over time, the vasocentricity is one of the most specific [61], in line
with the generally accepted pathogenic theory that the early formation of a demyelinating focal
area—an MS lesion—depends on the entry of lymphocytes and other inflammatory cells from the
systemic circulation into the central nervous system across the blood–brain barrier [1]. WM lesions
in MS, following the parenchymal venous topography (mainly at the level of small and medium
veins), are commonly found in periventricular, infratentorial and medullary areas (deep venous
system), as well as in juxtacortical regions (superficial venous system) and within the optic nerve
(central retinal vein). Therefore, the careful evaluation of WM lesion distribution is certainly helpful in
distinguishing MS from its MRI mimics, although some of them can involve the same areas, leading
to image misinterpretation [62]. An elevated concentration of deoxyhemoglobin—higher oxygen
consumption—and increased venous diameters—increased venous flow—at the inflamed site could be
some of the reasons for peculiar vessel evidence by MR venography in MS lesions [63], even though
this is still a topic of investigation.
One of the goals of our study was to investigate the optimal cut-off for WM lesions showing the
CVS to differentiate between MS and other diseases. The cut-off values for the proportion of lesions
with the CVS for the diagnosis of MS at the single-patient level ranged from 0 to 100. We found an
optimal threshold of 40%, that has been reported in several single studies [9,10,27,31,33,34,46,48,53],
confirming this threshold as an excellent value with a sensitivity of 90% and a specificity of 89%.
However, manually counting and visually detecting the presence of the CVS for each lesion is very
time consuming, influenced by both intra- and inter-observer variability and prone to error due to
repetitiveness and the tiredness of the observer performing the task. Therefore, reliable and robust
complete automatic detection and counting are highly desirable. A few attempts have been made
based on classical machine learning and novel deep learning methods [64,65] but further studies to
validate these promising methods are needed. A portion of the studies included in this review used
the FLAIR* approach [18], but the analyses included in this study did not provide any difference in the
proportion of detectable CVS-positive lesions when using this approach with respect to others. The
limited number of studies employing this method available for this review might have influenced this
result, however, this approach might be rarely accessible in a clinical setting since to produce FLAIR*
images, processing steps such as coregistration and multiplication, often not implemented directly in
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MRI scanners, are necessary. Another interesting aspect highlighted by this examination is that both the
choice of the sequence as well as the scanner field strength play an important role in the identification
of the CVS. As expected, the higher signal-to-noise ratio and contrast-to-noise ratio of high-field MRI
scanners do contributes to better delineate and detect the CVS (0.82), however, we found that the
use of 3T scanner might be sufficient in this regard (0.74), whereas the use of 1.5T scanners showed a
statistically significant reduction in CSV detection (0.58). Among sequences, we found a statistically
significant improvement of the CVS proportion detected in MS lesions using a 3D-EPI sequence versus
all other sequences (0.82 vs. 0.71) regardless of the field strength. However, this particular sequence
is not routinely used, perhaps due to the unavailability of a standard product sequence from some
manufacturers. Therefore, a standardization and a larger study on this aspect should be envisaged.
Another aspect that should be better investigated is the use of the contrast agent with this particular
sequence. A quantitative evaluation of the beneficial use of the contrast agent in the detection of the
CVS has not yet been performed, nevertheless, some studies [16,66,67] reported a notable improvement
in this regard.
Two meta-analyses of using the CVS in MS were performed recently [21,22]. Our results are in
agreement with Suh et al. [21], showing a similar proportion of lesions with the CVS and a slightly
lower optimal cut-off value of 40% compared to 45%, even if this does not include the largest European
multicenter study on the diagnostic value of the CVS in MS to date [51]. We further provide insight on
the use of the 3D-EPI sequence and we also found a significantly different proportion of MS lesions
with the CVS by comparing 1.5T and 3T scanners, suggesting that 3T scanners might provide a better
performance. A more recent meta-analysis [22] was performed only with 1.5T and 3T and provided a
lower proportion of MS lesions with the CVS than our findings, suggesting a threshold of 45% for the
differentiation of MS from radiological mimics, however, this study included only a small portion of
the articles included in our review.
Nevertheless, this work has some limitations. Regarding publication bias, we verified that the
proportional analysis did not show any significant publication bias effect, while the pooled specificity
and sensitivity analysis reported a publication bias assessed by Deeks’ funnel plot and the regression
test on the diagnostic odds ratio (p < 0.001), suggesting that the diagnostic performances could have
been overestimated. We have included studies with a control population composed of heterogeneous
mimicking disease spectra and also healthy controls that are vulnerable to selection bias. The studies
included are even more heterogeneous in terms of the number of subjects (range: 5–323) as well
as scanner field strength, sequence and post-processing technique used. Taking together the above
reported limitations, special care should be taken when using the CSV in routine clinical practice.
5. Conclusions
Despite the high heterogeneity of the studies included in this meta-analysis, the CVS in
differentiating MS lesions from other confounding disease could be used. We do highlight that
the minimum scanner field strength needed to better exploit the CVS specificity is 3T, and the
T2*-weighted 3D-EPI sequence could be suggested as a preferable image acquisition strategy.
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37. Lamot, U.; Avsenik, J.; Šega, S.; Šurlan Popovič, K. Presence of central veins and susceptibility weighted
imaging for evaluating lesions in multiple sclerosis and leukoaraiosis. Mult. Scler. Relat. Disord. 2017, 13,
67–72. [CrossRef] [PubMed]
Diagnostics 2020, 10, 1025 14 of 15
38. Sparacia, G.; Agnello, F.; Gambino, A.; Sciortino, M.; Midiri, M. Multiple sclerosis: High prevalence of
the “central vein” sign in white matter lesions on susceptibility-weighted images. Neuroradiol. J. 2018, 31,
356–361. [CrossRef] [PubMed]
39. Do Amaral, L.L.F.; Fragoso, D.C.; Nunes, R.H.; Littig, I.A.; da Rocha, A.J. gadolinium-enhanced
susceptibility-weighted imaging in multiple sclerosis: Optimizing the recognition of active plaques for
different mr imaging sequences. AJNR Am. J. Neuroradiol. 2019, 40, 614–619. [CrossRef]
40. Eisele, P.; Fischer, K.; Szabo, K.; Platten, M.; Gass, A. Characterization of contrast-enhancing and
non-contrast-enhancing multiple sclerosis lesions using susceptibility-weighted imaging. Front. Neurol.
2019, 10, 1082. [CrossRef]
41. Hosseini, Z.; Matusinec, J.; Rudko, D.A.; Liu, J.; Kwan, B.Y.M.; Salehi, F.; Sharma, M.; Kremenchutzky, M.;
Menon, R.S.; Drangova, M. Morphology-specific discrimination between ms white matter lesions and benign
white matter hyperintensities using ultra-high-field mri. AJNR Am. J. Neuroradiol. 2018, 39, 1473–1479.
[CrossRef] [PubMed]
42. Lane, J.I.; Bolster, B.; Campeau, N.G.; Welker, K.M.; Gilbertson, J.R. Characterization of multiple sclerosis
plaques using susceptibility-weighted imaging at 1.5 T: Can perivenular localization improve specificity of
imaging criteria? J. Comput. Assist. Tomogr. 2015, 39, 317–320. [CrossRef] [PubMed]
43. Öztoprak, B.; Öztoprak, I.; Yıldız, Ö.K. The effect of venous anatomy on the morphology of multiple sclerosis
lesions: A susceptibility-weighted imaging study. Clin. Radiol. 2016, 71, 418–426. [CrossRef] [PubMed]
44. Rogers, D.M.; Shah, L.M.; Wiggins, R.H. 3rd the central vein: Flair signal abnormalities associated with
developmental venous anomalies in patients with multiple sclerosis. AJNR Am. J. Neuroradiol. 2018, 39,
2007–2013. [CrossRef]
45. Gaitán, M.I.; Sati, P.; Inati, S.J.; Reich, D.S. Initial investigation of the blood-brain barrier in MS lesions at 7
tesla. Mult. Scler. Houndmills Basingstoke Engl. 2013, 19, 1068–1073. [CrossRef]
46. Samaraweera, A.P.R.; Falah, Y.; Pitiot, A.; Dineen, R.A.; Morgan, P.S.; Evangelou, N. The MRI central vein
marker; differentiating PPMS from RRMS and ischemic SVD. Neurol. Neuroimmunol. Neuroinflamm. 2018, 5.
[CrossRef]
47. Al-Zandi, S.H.; Fayadh, N.A.H.; Al-Waely, N.K.N. Central vein sign detected by SWI at 3 T MRI as a
discriminator between multiple sclerosis and leukoaraiosis. Egypt. J. Radiol. Nucl. Med. 2018, 49, 158–164.
[CrossRef]
48. Clarke, M.A.; Pareto, D.; Pessini-Ferreira, L.; Arrambide, G.; Alberich, M.; Crescenzo, F.; Cappelle, S.;
Tintoré, M.; Sastre-Garriga, J.; Auger, C.; et al. Value of 3T Susceptibility-Weighted Imaging in the Diagnosis
of Multiple Sclerosis. AJNR Am. J. Neuroradiol. 2020. [CrossRef]
49. Tallantyre, E.C.; Morgan, P.S.; Dixon, J.E.; Al-Radaideh, A.; Brookes, M.J.; Evangelou, N.; Morris, P.G. A
comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Investig. Radiol.
2009, 44, 491–494. [CrossRef]
50. Wuerfel, J.; Sinnecker, T.; Ringelstein, E.B.; Jarius, S.; Schwindt, W.; Niendorf, T.; Paul, F.; Kleffner, I.; Dörr, J.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult. Scler.
Houndmills Basingstoke Engl. 2012, 18, 1592–1599. [CrossRef]
51. Sinnecker, T.; Clarke, M.A.; Meier, D.; Enzinger, C.; Calabrese, M.; De Stefano, N.; Pitiot, A.; Giorgio, A.;
Schoonheim, M.M.; Paul, F.; et al. Evaluation of the central vein sign as a diagnostic imaging biomarker in
multiple sclerosis. JAMA Neurol. 2019, 76. [CrossRef] [PubMed]
52. Darwish, E.A.F.; Ibrahim, Y.A.; Zamzam, D.A. Value of central vein sign in discriminating multiple sclerosis
plaques from other white matter lesions. Egypt. J. Radiol. Nucl. Med. 2018, 49, 165–171. [CrossRef]
53. George, I.C.; Sati, P.; Absinta, M.; Cortese, I.C.; Sweeney, E.M.; Shea, C.D.; Reich, D.S. Clinical 3-tesla FLAIR*
MRI improves diagnostic accuracy in multiple sclerosis. Mult. Scler. Houndmills Basingstoke Engl. 2016, 22,
1578–1586. [CrossRef] [PubMed]
54. Lummel, N.; Boeckh-Behrens, T.; Schoepf, V.; Burke, M.; Brückmann, H.; Linn, J. Presence of a central vein
within white matter lesions on susceptibility weighted imaging: A specific finding for multiple sclerosis?
Neuroradiology 2011, 53, 311–317. [CrossRef] [PubMed]
55. Luo, J.; Yablonskiy, D.A.; Hildebolt, C.F.; Lancia, S.; Cross, A.H. Gradient echo magnetic resonance imaging
correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions. Mult. Scler.
Houndmills Basingstoke Engl. 2014, 20, 349–355. [CrossRef]
Diagnostics 2020, 10, 1025 15 of 15
56. Grabner, G.; Dal-Bianco, A.; Schernthaner, M.; Vass, K.; Lassmann, H.; Trattnig, S. Analysis of multiple
sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI. J. Magn. Reson. Imaging
2011, 33, 543–549. [CrossRef] [PubMed]
57. Samaraweera, A.P.R.; Clarke, M.A.; Whitehead, A.; Falah, Y.; Driver, I.D.; Dineen, R.A.; Morgan, P.S.;
Evangelou, N. The central vein sign in multiple sclerosis lesions is present irrespective of the T2* sequence at
3 T. J. Neuroimaging Off. J. Am. Soc. Neuroimaging 2017, 27, 114–121. [CrossRef]
58. Sinnecker, T.; Dörr, J.; Pfueller, C.F.; Harms, L.; Ruprecht, K.; Jarius, S.; Brück, W.; Niendorf, T.; Wuerfel, J.;
Paul, F. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis.
Neurology 2012, 79, 708–714. [CrossRef]
59. Gaitán, M.I.; de Alwis, M.P.; Sati, P.; Nair, G.; Reich, D.S. Multiple sclerosis shrinks intralesional, and enlarges
extralesional, brain parenchymal veins. Neurology 2013, 80, 145–151. [CrossRef]
60. Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.;
Filippi, M.; Freedman, M.S.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol. 2018, 17, 162–173. [CrossRef]
61. Hickey, W.F. The pathology of multiple sclerosis: A historical perspective1Supported in part by award NS
27321.1. J. Neuroimmunol. 1999, 98, 37–44. [CrossRef]
62. Liu, S.; Kullnat, J.; Bourdette, D.; Simon, J.; Kraemer, D.F.; Murchison, C.; Hamilton, B.E. Prevalence of brain
magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among
headache patients. Mult. Scler. J. 2013, 19, 1101–1105. [CrossRef] [PubMed]
63. Dal-Bianco, A.; Hametner, S.; Grabner, G.; Schernthaner, M.; Kronnerwetter, C.; Reitner, A.; Vass, C.;
Kircher, K.; Auff, E.; Leutmezer, F.; et al. Veins in plaques of multiple sclerosis patients—A longitudinal
magnetic resonance imaging study at 7 Tesla. Eur. Radiol. 2015, 25, 2913–2920. [CrossRef] [PubMed]
64. Maggi, P.; Fartaria, M.J.; Jorge, J.; La Rosa, F.; Absinta, M.; Sati, P.; Meuli, R.; Du Pasquier, R.; Reich, D.S.;
Cuadra, M.B.; et al. CVSnet: A machine learning approach for automated central vein sign assessment in
multiple sclerosis. NMR Biomed. 2020, 33, e4283. [CrossRef] [PubMed]
65. Dworkin, J.D.; Sati, P.; Solomon, A.; Pham, D.L.; Watts, R.; Martin, M.L.; Ontaneda, D.; Schindler, M.K.;
Reich, D.S.; Shinohara, R.T. Automated integration of multimodal mri for the probabilistic detection of the
central vein sign in white matter lesions. AJNR Am. J. Neuroradiol. 2018, 39, 1806–1813. [CrossRef]
66. Raz, E.; Pontecorvo, S.; Barra, V.; Marincola, B.C.; Morreale, M.; Tinelli, E.; Saba, L.; Di Paolo, P.L.; Aceti, A.;
Catalano, C.; et al. MR venography in patients with multiple sclerosis and correlation with clinical and MRI
parameters. J. Neuroimaging Off. J. Am. Soc. Neuroimaging 2014, 24, 492–497. [CrossRef]
67. Maggi, P.; Mazzoni, L.N.; Moretti, M.; Grammatico, M.; Chiti, S.; Massacesi, L. SWI enhances vein detection
using gadolinium in multiple sclerosis. Acta Radiol. Open 2015, 4, 2047981614560938. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
